



an Open Access Journal by MDPI

Iron Metabolism in Cancer

Guest Editors:

Dr. Margherita Correnti

Department of Biomedical
Sciences for Health, University of
Milan, Via Mangiagalli 31, 20133
Milan, Italy

Dr. Stefania Recalcati

Department of Biomedical
Sciences for Health, University of
Milan, Via Mangiagalli 31, 20133
Milan, Italy

Dr. Elena Gammella

Department of Biomedical
Sciences for Health, University of
Milan, Via Mangiagalli 31, 20133
Milan, Italy

Deadline for manuscript
submissions:

closed (30 April 2024)

Message from the Guest Editors

It has been shown that tumor cells display unique metabolic and bioenergetic features, including deregulation in iron metabolism. Several studies have shown that the reprogramming of iron metabolism is a key function for a cancer cell and that the disruption of iron homeostasis may play an important role in cancer development and progression. This Special Issue will provide insights into changes occurring in iron metabolism during carcinogenesis, with a particular focus on the influence of the microenvironment on it. In fact, an increasing number of studies support the role of the surrounding tumor microenvironment in regulating tumor cell metabolic plasticity. Moreover, a general metabolic rewiring can be observed in cancer cells upon the reprogramming of iron metabolism, favoring tumor development, survival, and metastasis development. Hence, the Special Issue will also aim to explore how dysregulation in iron metabolism may influence the other metabolic pathways in tumor cells, highlighting the importance of targeting iron metabolism as a novel therapeutic strategy for tumors.



mdpi.com/si/188173

Special Issue



an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Felipe Fregni

1. Neuromodulation Center and
Center for Clinical Research

Learning, Spaulding
Rehabilitation Hospital and
Massachusetts General Hospital,
Harvard Medical School, Boston,
MA 02114, USA

2. Department of Epidemiology,
Harvard T.H. Chan School of
Public Health, Boston, MA 02115,
USA

Message from the Editor-in-Chief

Biomedicines (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to *Biomedicines*, be it original research, review articles, or developing Special Issues of current key topics.

Author Benefits

Open Access: free for readers, with [article processing charges \(APC\)](#) paid by authors or their institutions.

High Visibility: indexed within [Scopus](#), [SCIE \(Web of Science\)](#), [PubMed](#), [PMC](#), [CAPUS / SciFinder](#), and [other databases](#).

Journal Rank: JCR - Q1 (*Pharmacology & Pharmacy*) / CiteScore - Q2 (*Medicine (miscellaneous)*)

Contact Us

Biomedicines Editorial Office
MDPI, St. Alban-Anlage 66
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/biomedicines
biomedicines@mdpi.com
[X@Biomed_MDPI](#)